QurAlis Announces Topline Data From its Phase 1 Clinical Trial of QRL-101 Evaluating Biomarkers of ALS and Epilepsy in Healthy Volunteers
Results demonstrated statistically significant effects on biomarkers that predict ALS disease progression and severity